Resumen:
The evolution of neurocognitive performance in aviremic human immunodeficiency virus (HIV)–
positive patients treated with <3 antiretrovirals is unknown.
Methods. We prospectively included aviremic (≥1 year) HIV-positive patients, without concomitant major neurocognitive
confounders, currently receiving boosted lopinavir or darunavir as monotherapy (n = 67) or triple antiretroviral
therapy (ART) (n = 67) for ≥1 year. We evaluated neurocognitive function (7 domains) at baseline and
after 1 year.We performed analysis of covariance to evaluate if 1 additional year of exposure tomonotherapy compared
with triple ART had an effect on Global Deficit Score (GDS) changes after adjustment for potential confounders. We
also compared the evolution of neurocognitive performance and impairment rates.
Results. Intention-to-treat analysis showed that monotherapy did not influence 1-year GDS change after adjustment
for significant confounders (age, ethnicity, duration of therapy, hepatitis C virus status, and HOMA-IR index); the
adjusted effect was −0.04 (95% confidence interval, −.14 to .05; P = .38). Neurocognitive stability was observed with
monotherapy and triple therapy (GDS crude mean ...